(e) Compensation Arrangements of Certain Officers and Directors

On February 5, 2013, the Compensation Committee (the "Committee") of the Board of Directors (the "Board") approved 2013 base salaries and 2013 equity awards for the executive officers, including the named executive officers, of Dynavax other than the CEO and the President. Also on February 5, 2013, the Board determined there would be no change to the base salaries of Dynavax's CEO, its President, and its Chief Financial Officer.

The Board and the Committee annually evaluate the performance and determine the compensation of Dynavax's executive officers.

The 2013 base salaries and 2013 equity awards approved by the Board and Committee are as set forth below:

                                                                2013 Base          2013 Equity
Name and Title                                                    Salary            Award (1)
Robert L. Coffman, Ph.D.                                        $  282,622              180,000
Vice President and Chief Scientific Officer

Jennifer Lew                                                    $  250,000              150,000
Vice President, Finance

Michael S. Ostrach                                              $  342,176              200,000
Vice President, Chief Business Officer and General Counsel

Stephen Tuck                                                    $  348,140              200,000
Vice President, Global Technical Operations

(1) Stock options with an exercise price per share of $3.08, representing the closing price on the grant date of February 5, 2013. All options will vest over four (4) years with one fourth (1/4) of the shares subject to the option vesting twelve months after the grant date, and one forty-eighth (1/48) of the shares subject to the option vesting on the last day of each month thereafter.